155 related articles for article (PubMed ID: 36623474)
1. Authors reply to the comment on letters to the editor in oral oncology referring to microRNAs as therapeutic molecules for oral squamous cell carcinoma.
Sekar D
Oral Oncol; 2023 Feb; 137():106306. PubMed ID: 36623474
[No Abstract] [Full Text] [Related]
2. Comment on letters to the editor in oral oncology referring to microRNAs as therapeutic molecules for oral squamous cell carcinoma.
Zhang S; Han X; Wang M; Shen X
Oral Oncol; 2023 Feb; 137():106298. PubMed ID: 36584496
[No Abstract] [Full Text] [Related]
3. Comment on circulatory miRNAs as therapeutic molecules for oral potentially malignant disorder and oral squamous cell carcinoma.
Yang X; Zhou T; Ji T; Jia H; Liu W
Oral Oncol; 2022 Jul; 130():105901. PubMed ID: 35533509
[No Abstract] [Full Text] [Related]
4. Circulatory microRNAs inhibition and its signaling pathways in the treatment of oral squamous cell carcinoma (OSCC).
Sekar D
Oral Oncol; 2022 Mar; 126():105763. PubMed ID: 35144207
[No Abstract] [Full Text] [Related]
5. MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS.
Krishnan M; Babu S; Jayaraman S; Daniel P; Solomon A; Chinnaiyan M
Exp Oncol; 2022 Nov; 44(3):263-264. PubMed ID: 36325699
[No Abstract] [Full Text] [Related]
6. MicroRNA-138 and its targets: A therapeutic molecule for oral squamous cell carcinoma.
Selvakumar SC; K Auxzilia P; Dinesh Y; Senthilmurugan M; Sekar D
Oral Oncol; 2022 Jul; 130():105925. PubMed ID: 35606273
[No Abstract] [Full Text] [Related]
7. Therapeutic nature of microRNAs in Oral Squamous Cell Carcinoma (OSCC).
Sekar D; Selvakumar SC; Auxzilia Preethi K
Oral Oncol; 2022 Nov; 134():106106. PubMed ID: 36067592
[No Abstract] [Full Text] [Related]
8. Authors reply referring to the article published in oral oncology entitled Dysregulation and implications of lncRNAs and miRNAs in oral tongue squamous cell carcinoma: In reply with emphasis on the role of ceRNAs.
Sekar D
Oral Oncol; 2023 Mar; 138():106314. PubMed ID: 36689788
[No Abstract] [Full Text] [Related]
9. Resveratrol and miR-200c: insights into the prevention of oral squamous cell carcinoma.
Jayaraman S; Fathima SJ; Veeraraghavan VP; Raj AT; Patil S
Future Oncol; 2022 Oct; 18(31):3471-3472. PubMed ID: 36268781
[No Abstract] [Full Text] [Related]
10. MicroRNAs and cancer-associated fibroblasts in the tumour microenvironment of oral squamous cell carcinoma (OSCC).
Chandralekha Selvakumar S; Auxzilia Preethi K; Sekar D
Oral Oncol; 2022 Nov; 134():106124. PubMed ID: 36096044
[No Abstract] [Full Text] [Related]
11. Systematic review and individual patient data analysis of pediatric head and neck squamous cell carcinoma: An analysis of 217 cases.
Bhanu Prasad V; Mallick S; Upadhyay AD; Rath GK
Int J Pediatr Otorhinolaryngol; 2017 Jan; 92():75-81. PubMed ID: 28012539
[TBL] [Abstract][Full Text] [Related]
12. Engineered therapeutic bacteria for the treatment of oral squamous cell carcinoma.
Jayaseelan VP; A S SG; Arumugam P
Oral Oncol; 2022 Jul; 130():105874. PubMed ID: 35533508
[No Abstract] [Full Text] [Related]
13. Early Discovery, Early Recovery: The principle behind successful oral squamous cell carcinoma treatment!
Misra SR; Das R
Oral Oncol; 2023 Oct; 145():106511. PubMed ID: 37478573
[No Abstract] [Full Text] [Related]
14. Essentials of oral cancer.
Rivera C
Int J Clin Exp Pathol; 2015; 8(9):11884-94. PubMed ID: 26617944
[TBL] [Abstract][Full Text] [Related]
15. LncRNA ANRIL represses proliferation of oral squamous cell carcinoma cells through targeting MiR-99a.
Hang C; Zhang Y; Qu Y; Wang X
Minerva Med; 2022 Oct; 113(5):887-889. PubMed ID: 32697066
[No Abstract] [Full Text] [Related]
16. Potential use of salivary mRNA-based biomarkers to predict oral squamous cell carcinoma.
Tang KD; Weeramange CE; Vider J; Hartel G; West NP; McMillan NAJ; Batstone MD; Liu Z; Vasani S; Kenny L; Punyadeera C
Oral Oncol; 2022 Dec; 135():106215. PubMed ID: 36274347
[No Abstract] [Full Text] [Related]
17. Reply to Letter to the Editor regarding "Lymph node characteristics and their prognostic significance in oral squamous cell carcinoma".
Arun I; Maity N; Hameed S; Jain PV; Manikantan K; Sharan R; Arun P
Head Neck; 2021 Aug; 43(8):2556. PubMed ID: 33964180
[No Abstract] [Full Text] [Related]
18. Outcomes for recurrent oral cavity squamous cell carcinoma: A comprehensive outlook.
Reghunadhan P; Hegde S; Thakur S; Subash A; Rao VUS
Oral Oncol; 2023 Aug; 143():106440. PubMed ID: 37290381
[No Abstract] [Full Text] [Related]
19. Methuosis - A promising lead for the treatment of oral squamous cell carcinoma.
Krishnan RP; Ramani P; Pandiar D
J Stomatol Oral Maxillofac Surg; 2023 Feb; 124(1S):101333. PubMed ID: 36402427
[No Abstract] [Full Text] [Related]
20. Telomerase reverse transcriptase mutation: A risk predictor and drug target for oral squamous cell carcinoma and its precursors.
Yuwanati M; Sarode SC; Sarode GS; Gadbail A; Gondivkar S
Oral Oncol; 2022 Nov; 134():106120. PubMed ID: 36096049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
